Elios Vision Acquired by Bausch + Lomb in Strategic Glaucoma Market Expansion
Deal News | Jan 09, 2025 | Outcome Capital LLC
Outcome Capital, a specialized life sciences and healthcare advisory firm, has announced the acquisition of its client, Elios Vision, by Bausch + Lomb. Elios Vision has developed the ELIOS procedure, an innovative excimer laser-based minimally invasive glaucoma surgery (MIGS) procedure. This acquisition comes after years of strategic and financial guidance from Outcome Capital, which helped position Elios Vision as a key player in the glaucoma treatment market. By providing expert advisory services from inception through acquisition phases, Outcome Capital played a pivotal role in Elios Vision's growth and market positioning. The Elios procedure is notable for being implant-free and CE-marked for use in the EU, with U.S. FDA approval being sought this year. The acquisition is expected to enhance Bausch + Lomb's portfolio in glaucoma treatment, a market affecting over 76 million individuals globally.
Sectors
- Life Sciences
- Healthcare
- Investment Banking
Geography
- United States – Outcome Capital and Elios Vision are based in the U.S., and there is a mention of seeking FDA approval for Elios' technology in the U.S.
- European Union – The ELIOS procedure is already CE-marked and marketed in the European Union.
Industry
- Life Sciences – The article involves Outcome Capital, which is a specialized advisory firm in the life sciences sector, and deals with a company focused on glaucoma treatment.
- Healthcare – Elios Vision operates in the healthcare field by developing procedures for glaucoma treatment, impacting the healthcare industry significantly.
- Investment Banking – Outcome Capital provides investment banking services, specializing in the advisory and strategic guidance of Elios Vision leading to its acquisition.
Financials
- $2.5 billion – The estimated market size for glaucoma treatment, which Elios Vision's innovations target.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Elios Vision | Target Company | Companies | Developer of the ELIOS excimer laser-based MIGS procedure for glaucoma treatment. |
| Bausch + Lomb | Acquirer | Companies | A global eye health company acquiring Elios Vision to enhance its glaucoma treatment portfolio. |
| Outcome Capital | Advisory Firm | Companies | Strategic advisory and investment banking firm that guided Elios Vision through the acquisition process. |